Jacobs Levy Equity Management Portfolio holdings

Jacobs Levy Equity Management's Q1 2014 Portfolio in Review

As of Q1 2014, Jacobs Levy Equity Management held 1,150 positions worth $5.97B, down 10% from $6.66B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Jacobs Levy Equity Management withdrew a net $778M in Q1 2014, closing 276 positions and reducing 398 holdings. Its most notable exit was Allergan Inc, an estimated $52.2M position sold in full.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Industrials and Financials.

Against the trend, Jacobs Levy Equity Management opened a new position in Bristol-Myers Squibb worth $35.5M.

• Jacobs Levy Equity Management's largest Q1 2014 buy was Bristol-Myers Squibb: 683,110 shares worth $35.5M.
• Jacobs Levy Equity Management added most to Amazon in Q1 2014, an estimated $51.8M increase.
• Jacobs Levy Equity Management's biggest Q1 2014 reduction was Eli Lilly, cutting an estimated $40.3M.
• Jacobs Levy Equity Management fully exited Allergan Inc in Q1 2014, selling an estimated $52.2M.
• Jacobs Levy Equity Management's ten largest holdings make up 12% of its $5.97B portfolio in Q1 2014.
• Jacobs Levy Equity Management opened 217 new positions and closed 276 in Q1 2014.
• Jacobs Levy Equity Management's portfolio value fell 10% quarter-over-quarter to $5.97B.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2014, filed 15 May 2014.